IDEMIA Partners With KT Corporation to Support Launch of Asia-Pacific’s 1st 5G Standalone Network and 5G SIM
IDEMIA will supply KT Corporation its eXtra One 5G USIM (Universal Subscriber Identity Module), a dedicated 5G SIM card giving enhanced subscriber privacy protection and fast, seamless connectivity in South Korea, while marking a big development leap forward and boosting consumer 5G handset adoption.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005442/en/
(Photo: Business Wire)
IDEMIA, the global leader in Augmented Identity, today announced it plans to team up with KT Corporation (formerly Korea Telecomm) to launch KTC’s first standalone (SA) 5G USIM card in Asia-Pacific in support of their new 5G standalone network.
Under this partnership, IDEMIA will supply KTC 5G standalone USIM cards with NFC (near-field communication) features. The 5G standalone USIM delivers better security for MNO (Mobile Network Operator) network customers as the cards are specially designed to protect customer privacy. Through the USIMs IMSI (International Mobile Subscriber Identity) encryption capability, MNO customer private data such as location and network usage habits will be protected by the fact that mobile users’ IMSI numbers are encrypted before transmission to networks. The card safeguards MNOs’ control over their 5G security and data. Compliant with global privacy regulations and recommended by the Trusted Connectivity Alliance (TCA), 5G USIM cards are also compatible with 5G non-stand alone (NSA) networks, 4G networks and South Korea’s NFC contactless payment schemes.
“We constantly push the boundaries at IDEMIA, and launching our eXtra One 5G SA USIM cards in Asia for the first time is testament to this. We have worked with KT Corporation for many years going back to the 3G era, and we are thrilled to join forces once more to bring to market a truly groundbreaking product. We look forward to support their efforts in delivering a smoother, more modern experience to South Korean customers,” said Benson Yeo, IDEMIA Asia Pacific Mobile Operators Vice President.
“It’s just a matter of time before 5G becomes the new global communication standard. We partner with IDEMIA to stay ahead of the curve and ensure that our users’ privacy and data are totally safe while they enjoy the benefits of our 5G networks. Our past great teamwork with IDEMIA gives us confidence they have the expertise and capability to create these game-changing 5G SA USIM cards for our customers”, said Joon-Ho Lee, Device Team Leader, Device Division, KT Corporation.
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
About IDEMIA’s Mobile Operators Business unit
IDEMIA serves clients in 180 countries and is trusted by over 500 mobile operators globally. With over 900 million SIM cards, 100 + eSIM platform references and over 2.2 eSIM consumer transactions in 2020, IDEMIA is leading the way in eSIM and remote subscription management for consumer and M2M spaces and end-to-end biometric solutions. Making MNOs the next identity providers. IDEMIA benefits from its global manufacturing footprint (Brazil, France, India and China) and cutting-edge security data centers in Europe and the United States. Our solutions are trusted by the largest Groups worldwide. Our continuous innovation is fueled by strong R&D investments and close partnerships in IoT/M2M - Connectivity - Biometrics – Security – Encryption – QoS/QoE – Advanced SIM & services areas.
About KT Corporation
KT Corp., Korea's largest telecommunications service provider, is leading the new era of innovations in one the world's most connected countries with 5G, Big Data, Cloud, IoT, Blockchain and other transformative technologies. KT launched the world's first nationwide commercial 5G network in April 2019, after showcasing the first trial 5G services at the PyeongChang Winter Olympic Games in February 2018. To help cope with COVID-19, KT is staging a social campaign, dubbed "Ma-Eum:TACT (Heart to Heart)," providing technology support for people and businesses in need. KT will deliver most essential and innovative services and solutions to its customers around the world as the first frontier in the next technology revolution and number one Global ICT Company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
+65 9644 5927
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ipsen: ESMO 2021: Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer18.9.2021 07:30:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced presentation of new analyses at the European Society for Medical Oncology (ESMO) Congress 2021 across different forms of cancer for people treated with Cabometyx® (cabozantinib). Of note, the final analysis of the pivotal Phase III COSMIC-311 trial (Abstract LBA67) will be presented, with Cabometyx demonstrating a clinically meaningful, sustained efficacy benefit versus placebo in people living with previously treated radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). With a median follow-up of 10.1 months, Cabometyx continued to demonstrate superior median progression-free survival (mPFS) with a reduction in the risk of disease progression or death of 78% versus placebo (hazard ratio [HR]: 0.22, 96% confidence interval [CI]: 0.15-0.32; p<0.0001).1 This final analysis is consistent with data from the interim analysis, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021
Unifrax Hosts Groundbreaking Ceremony for SiFAB™ Manufacturing Line17.9.2021 21:46:00 EEST | Press release
Today, Unifrax, a leading manufacturer of high-performance specialty materials, held a ceremonial event celebrating its first large-scale SiFAB™ Silicon Fiber Anode Battery Technology manufacturing line, which is currently under construction at the company’s north central Indiana facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210917005495/en/ Unifrax team celebrates SiFAB groundbreaking at New Carlisle plant. (Photo: Business Wire) The event recognized Unifrax’s ongoing partnership with the State of Indiana and St. Joseph County, along with SiFAB’s continued progress. Unifrax executives, along with the SiFAB manufacturing team and local and state government officials, kicked off the ceremony at 10 a.m. EDT at the New Carlisle, IN plant, with remarks by John Dandolph, president and CEO, Unifrax. “Through the support of the State of Indiana and St. Joseph County, we have the ability to leverage our existing New Carli
Prince William announces 15 Finalists for inaugural year of the £50 million Earthshot Prize17.9.2021 20:01:00 EEST | Press release
The Earthshot Prize announces today its first-ever shortlist of 15 Finalists, each with a chance of winning £1million to support their innovative environmental solutions to the greatest challenges facing the planet. Prince William said: "Over half a century ago, President Kennedy’s ‘Moonshot’ programme united millions of people around the goal of reaching the moon. Inspired by this, The Earthshot Prize aims to mobilise collective action around our unique ability to innovate, problem solve and repair our planet. “I am honoured to introduce the 15 innovators, leaders, and visionaries who are the first ever Finalists for The Earthshot Prize. They are working with the urgency required in this decisive decade for life on Earth and will inspire all of us with their optimism in our ability to rise to the greatest challenges in human history.” Launched by Prince William and The Royal Foundation in October 2020, The Earthshot Prize is the most prestigious global environment prize in history. Li
Wipro Announces Co-innovation Space with Google Cloud17.9.2021 16:32:00 EEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the launch of the Wipro-Google Cloud Innovation Arena in Bangalore, India. This cloud collaboration space will provide in-house technical expertise, ensure seamless cloud adoption, and accelerate innovation to drive business transformation for customers. By combining the expertise and resources of Wipro FullStride Cloud Services and Google Cloud, this jointly developed innovation center will offer a unique combination of people, processes, and platforms that will collectively create a futuristic experience for customers globally. This state-of-the-art arena will showcase the talent, tools and best practices required to develop and deploy applications on Google Cloud. Jason Eichenholz, Senior Vice President, Global Head of Ecosystems & Partnerships, Wipro Limited said, “We are excited to strengthen our partnership with Google Clou
Zynga Announces ReVamp, the First Multiplayer Social Deception Game For Snapchat17.9.2021 16:00:00 EEST | Press release
Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, announced today that ReVamp, an upcoming multiplayer social deception game, will launch soon in select markets exclusively for Snapchat. The vampire-themed game will be the first social deception title on Snapchat, giving Snapchatters their first chance to sink their teeth into this popular genre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210917005012/en/ Zynga Announces ReVamp, the First Multiplayer Social Deception Game For Snapchat (Graphic: Business Wire) ReVamp is a real-time multiplayer imposter game where players aim to reveal who the vampire player is among their group of friends while they renovate the rooms of an old mansion. In the game, human players must complete renovation tasks, such as demolition and building, to improve their chances of survival while identifying and defeating the vampire during the voting phase. Vampire players mu
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia17.9.2021 15:00:00 EEST | Press release
BeiGene (NASDAQ: BGNE; HKEX: 06160) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or first-line treatment for patients unsuitable for chemo-immunotherapy. “Bruton’s tyrosine kinase (BTK) inhibitors have emerged as a promising treatment for WM, yet treatment discontinuation due to lack of response or side effects remains a concern,” said Prof. Christian Buske, Medical Director at the University Hospital Ulm, Germany, and a trial investigator of the ASPEN study. “The ASPEN trial demonstrated that BRUKINSA provided deep and durable responses and offered substantial improvements in safety and tolerability over standard therapy. Patients in Europe with WM may soon have a new treatment option that can offer improved outcomes.
Janssen Receives Positive CHMP Opinion for BYANNLI® (6-monthly Paliperidone Palmitate) for the Maintenance Treatment of Schizophrenia in Adults17.9.2021 13:50:00 EEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending the long-acting atypical antipsychotic therapy BYANNLI® (6-monthly paliperidone palmitate; PP6M) for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1-monthly paliperidone palmitate (PP1M)2 or 3-monthly paliperidone palmitate (PP3M).3 If approved by the European Commission, PP6M will provide the first twice-yearly treatment for adults living with schizophrenia and longest available dosing interval for an antipsychotic medication in the European Economic Area.1,4 “With only two injections per year, 6-monthly paliperidone palmitate has the potential to reduce the burden of taking medication frequently, giving eligible patients the opportunity to focus on other aspects of their life,” said Ludovic de Beaucoudrey, Ph.D., EMEA Therape
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom